Literature DB >> 28233126

Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin.

Christina Oxlund1, Birgül Kurt2, Ilona Schwarzensteiner2, Mie R Hansen3, Mette Stæhr3, Per Svenningsen3, Ib A Jacobsen4, Pernille B Hansen3, Anne D Thuesen3, Anja Toft5, Gitte R Hinrichs3, Claus Bistrup6, Boye L Jensen3.   

Abstract

The proteinase prostasin is a candidate mediator for aldosterone-driven proteolytic activation of the epithelial sodium channel (ENaC). It was hypothesized that the aldosterone-mineralocorticoid receptor (MR) pathway stimulates prostasin abundance in kidney and urine. Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial. Prostasin protein level was assessed by immunoblotting in (1) human and rat urines with/without nephrotic syndrome, (2) human nephrectomy tissue, (3) urine and kidney from aldosterone synthase-deficient (AS-/-) mice and ANGII- and aldosterone-infused mice, and in (4) kidney from adrenalectomized rats. Serum aldosterone concentration related to prostasin concentration in urine but not in plasma. Plasma prostasin concentration increased significantly after spironolactone compared to control. Urinary prostasin and albumin related directly and were reduced by spironolactone. In patients with nephrotic syndrome, urinary prostasin protein was elevated compared to controls. In rat nephrosis, proteinuria coincided with increased urinary prostasin, unchanged kidney tissue prostasin, and decreased plasma prostasin while plasma aldosterone was suppressed. Prostasin protein abundance in human nephrectomy tissue was similar across gender and ANGII inhibition regimens. Prostasin urine abundance was not different in AS-/- and aldosterone-infused mice. Prostasin kidney level was not different from control in adrenalectomized rats and AS-/- mice. We found no evidence for a direct relationship between mineralocorticoid receptor signaling and kidney and urine prostasin abundance. The reduction of urinary prostasin in spironolactone-treated patients is most likely the result of an improved glomerular filtration barrier function and generally reduced proteinuria.

Entities:  

Keywords:  Adrenal; Aldosterone synthase; Epithelial sodium channel; Nephrotic syndrome; Proteolysis

Mesh:

Substances:

Year:  2017        PMID: 28233126     DOI: 10.1007/s00424-017-1938-6

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  38 in total

1.  Prostasin is a glycosylphosphatidylinositol-anchored active serine protease.

Authors:  L M Chen; M L Skinner; S W Kauffman; J Chao; L Chao; C D Thaler; K X Chai
Journal:  J Biol Chem       Date:  2001-03-26       Impact factor: 5.157

2.  The epithelial sodium channel γ-subunit is processed proteolytically in human kidney.

Authors:  Rikke M Zachar; Karsten Skjødt; Niels Marcussen; Steen Walter; Anja Toft; Maria R Nielsen; Boye L Jensen; Per Svenningsen
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

3.  Direct and Indirect Mineralocorticoid Effects Determine Distal Salt Transport.

Authors:  Andrew S Terker; Bethzaida Yarbrough; Mohammed Z Ferdaus; Rebecca A Lazelle; Kayla J Erspamer; Nicholas P Meermeier; Hae J Park; James A McCormick; Chao-Ling Yang; David H Ellison
Journal:  J Am Soc Nephrol       Date:  2015-12-28       Impact factor: 10.121

4.  Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice.

Authors:  Gene Lee; Natalia Makhanova; Kathleen Caron; Maria L Sequeira Lopez; R Ariel Gomez; Oliver Smithies; Hyung-Suk Kim
Journal:  Endocrinology       Date:  2005-02-24       Impact factor: 4.736

5.  Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation.

Authors:  Sarah Netzel-Arnett; Brooke M Currie; Roman Szabo; Chen-Yong Lin; Li-Mei Chen; Karl X Chai; Toni M Antalis; Thomas H Bugge; Karin List
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

6.  Plasmin in nephrotic urine activates the epithelial sodium channel.

Authors:  Per Svenningsen; Claus Bistrup; Ulla G Friis; Marko Bertog; Silke Haerteis; Bettina Krueger; Jane Stubbe; Ole Nørregaard Jensen; Helle C Thiesson; Torben R Uhrenholt; Bente Jespersen; Boye L Jensen; Christoph Korbmacher; Ole Skøtt
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

7.  Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin.

Authors:  Bin Fan; Thomas D Wu; Wei Li; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2005-08-15       Impact factor: 5.157

8.  Regulation of prostasin expression and function in the prostate.

Authors:  Li-Mei Chen; Xiaochun Zhang; Karl X Chai
Journal:  Prostate       Date:  2004-04-01       Impact factor: 4.104

9.  The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling.

Authors:  Kohei Uchimura; Manabu Hayata; Teruhiko Mizumoto; Yoshikazu Miyasato; Yutaka Kakizoe; Jun Morinaga; Tomoaki Onoue; Rika Yamazoe; Miki Ueda; Masataka Adachi; Taku Miyoshi; Naoki Shiraishi; Wataru Ogawa; Kazuki Fukuda; Tatsuya Kondo; Takeshi Matsumura; Eiichi Araki; Kimio Tomita; Kenichiro Kitamura
Journal:  Nat Commun       Date:  2014-03-11       Impact factor: 14.919

10.  Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation.

Authors:  Roman Szabo; Katiuchia Uzzun Sales; Peter Kosa; Natalia A Shylo; Sine Godiksen; Karina K Hansen; Stine Friis; J Silvio Gutkind; Lotte K Vogel; Edith Hummler; Eric Camerer; Thomas H Bugge
Journal:  PLoS Genet       Date:  2012-08-30       Impact factor: 5.917

View more
  2 in total

1.  Zymogen-locked mutant prostasin (Prss8) leads to incomplete proteolytic activation of the epithelial sodium channel (ENaC) and severely compromises triamterene tolerance in mice.

Authors:  Daniel Essigke; Alexandr V Ilyaskin; Matthias Wörn; Bernhard N Bohnert; Mengyun Xiao; Christoph Daniel; Kerstin Amann; Andreas L Birkenfeld; Roman Szabo; Thomas H Bugge; Christoph Korbmacher; Ferruh Artunc
Journal:  Acta Physiol (Oxf)       Date:  2021-03-11       Impact factor: 7.523

2.  Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

Authors:  Edmund Ym Chung; Marinella Ruospo; Patrizia Natale; Davide Bolignano; Sankar D Navaneethan; Suetonia C Palmer; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2020-10-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.